{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T05:56:23Z","timestamp":1794203783637,"version":"4.8.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1097\/rhu.0b013e318214f30c","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T17:57:40Z","timestamp":1355767060000},"page":"142-144","source":"Crossref","is-referenced-by-count":35,"title":["Rituximab in the Treatment of Bullous Systemic Lupus Erythematosus"],"prefix":"10.1097","volume":"17","author":[{"given":"Shamael","family":"Alsanafi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Kovarik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mermelstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P.","family":"Werth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210207","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1111\/j.1346-8138.2005.tb00894.x","article-title":"Bullous systemic lupus erythematosus as an initial manifestation of SLE.","volume":"32","author":"Fujimoto","year":"2005","journal-title":"J Dermatol"},{"key":"R2-7-20210207","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1365-2133.1995.tb16950.x","article-title":"Bullous systemic lupus erythematosus: revised criteria for diagnosis.","volume":"132","author":"Yell","year":"1995","journal-title":"Br J Dermatol"},{"key":"R3-7-20210207","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/0961203309106174","article-title":"Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases.","volume":"18","author":"Ramos-Casals","year":"2009","journal-title":"Lupus"},{"key":"R4-7-20210207","first-page":"495","article-title":"Rituximab in dermatological diseases.","volume":"144","author":"Troiano","year":"2009","journal-title":"G Ital Dermatol Venereol"},{"key":"R5-7-20210207","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","article-title":"Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action.","volume":"6","author":"Pescovitz","year":"2006","journal-title":"Am J Transplant"},{"key":"R6-7-20210207","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.clim.2008.01.011","article-title":"Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.","volume":"127","author":"Liossis","year":"2008","journal-title":"Clin Immunol"},{"key":"R7-7-20210207","first-page":"63","article-title":"Newer treatments for non-Hodgkin's lymphoma: monoclonal antibodies.","volume":"12","author":"Maloney","year":"1998","journal-title":"Oncology (Williston Park)"},{"key":"R8-7-20210207","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1365-2141.2009.07718.x","article-title":"Rituximab in non-haematological disorders of adults and its mode of action.","volume":"146","author":"McDonald","year":"2009","journal-title":"Br J Haematol"},{"key":"R9-7-20210207","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/art.10541","article-title":"An open study of B lymphocyte depletion in systemic lupus erythematosus.","volume":"46","author":"Leandro","year":"2002","journal-title":"Arthritis Rheum"},{"key":"R10-7-20210207","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/s10165-009-0213-x","article-title":"A perspective on B-cell-targeting therapy for SLE.","volume":"20","author":"Looney","year":"2010","journal-title":"Mod Rheumatol"},{"key":"R11-7-20210207","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/art.27233","article-title":"Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus.","volume":"62","author":"Merrill","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R12-7-20210207","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/11535420-000000000-00000","article-title":"B cell-targeted therapies for systemic lupus erythematosus, an update on clinical trial data.","volume":"70","author":"Looney","year":"2010","journal-title":"Drugs"},{"key":"R13-7-20210207","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3324\/haematol.10564","article-title":"Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen.","volume":"92","author":"Kolstad","year":"2007","journal-title":"Hematologica"}],"container-title":["JCR: Journal of Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RHU.0b013e318214f30c","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:55:42Z","timestamp":1620971742000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00124743-201104000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/rhu.0b013e318214f30c","relation":{},"ISSN":["1076-1608"],"issn-type":[{"value":"1076-1608","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]}}}